DK2556841T3 - Fremgangsmåde til hæmning af knogleresorption - Google Patents
Fremgangsmåde til hæmning af knogleresorption Download PDFInfo
- Publication number
- DK2556841T3 DK2556841T3 DK12180292.0T DK12180292T DK2556841T3 DK 2556841 T3 DK2556841 T3 DK 2556841T3 DK 12180292 T DK12180292 T DK 12180292T DK 2556841 T3 DK2556841 T3 DK 2556841T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- thr
- val
- pro
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Claims (13)
1. Anti-sclerostin-antistof eller fragment deraf til anvendelse ved en fremgangsmåde til inhibering af knogleresorption hos et menneske, hvilken fremgangsmåde omfatter at administrere anti-sclerostin-antistoffet eller fragmentet deraf til mennesket i en mængde på fra 1 mg/kg til 5 mg/kg, hvor anti-sclerostin-antistoffet eller fragmentet deraf udviser en bindingsaffinitet for sclerostin med SEQ ID No: 1 på mindre end eller lig med 1x10'7M og krydsblokerer bindingen til sclerostin af et antistof, der omfatter CDR’s med SEQ ID No: 245, 246, 247, 78, 79 og 80 eller CDR’s med SEQ ID No: 284, 285, 286, 296, 297 og 298, eller er krydsblokeret fra at binde til sclerostin ved hjælp af antistoffet, hvor: - SEQ ID No:245 = Asp Tyr Asn Met His; - SEQ ID No:246 = Glu Ile Asn Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gin Lys Phe Lys Gly; - SEQ ID No:247 = Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Val; - SEQ ID No: 78 = Arg Ala Ser Gin Asp Ile Ser Asn Tyr Leu Asn; - SEQ ID No: 79 = Tyr Thr Ser Arg Leu Leu Ser; og - SEQ ID No: 80 = Gin Gin Gly Asp Thr Leu Pro Tyr Thr; og - SEQ ID NO: 284 = Arg Ala Ser Ser Ser Val Thr Ser Ser Tyr Leu Asn; - SEQ ID NO: 285 = Ser Thr Ser Asn Leu Ala Ser; - SEQ ID NO: 286 = Gin Gin Tyr Asp Phe Phe Pro Ser Thr; - SEQ ID NO: 296 = Asp Tyr Tyr Met Asn; - SEQ ID NO: 297 = Asp He Asn Pro Tyr Asn Asp Asp Thr Thr Tyr Asn His Lys Phe Lys Gly; og - SEQ ID NO 298 = Glu Thr Ala Val He Thr Thr Asn Ala Met Asp.
2. Antistof eller fragment til anvendelse ifølge krav 1, hvor mængden af anti-sclerostin-antistof, der administreres, er fra 1 mg/kg til 3 mg/kg.
3. Antistof eller fragment til anvendelse ifølge krav 1 eller 2, hvor mængden af anti-sclerostin-antistof, der administreres, er ca. 2 mg/kg.
4. Antistof eller fragment til anvendelse ifølge krav 1 eller 2, hvor mængden af anti-sclerostin-antistof, der administreres, er ca. 3 mg/kg.
5. Antistof eller fragment til anvendelse ifølge krav 1, hvor fremgangsmåden omfatter at administrere anti-sclerostin-antistoffet til et menneske i en dosis på fra 70 til 450 mg.
6. Antistof eller fragment til anvendelse ifølge krav 1, hvor fremgangsmåden omfatter at administrere en dosis på ca. 140 mg.
7. Antistof eller fragment til anvendelse ifølge krav 1, hvor fremgangsmåden omfatter at administrere en dosis på ca. 210 mg.
8. Antistof eller fragment til anvendelse ifølge et af de foregående krav, hvor mængden af anti-sclerostin-antistof administreres til individet én gang hver fjortende dag.
9. Antistof eller fragment til anvendelse ifølge et af kravene 1 til 7, hvor anti-sclerostin-antistoffet administreres til individet én gang om måneden.
10. Antistof eller fragment til anvendelse ifølge et af de foregående krav, hvor antistoffet er et menneskeantistof, et humaniseret antistof, et monoklonalt antistof eller et kimærisk antistof.
11. Antistof eller fragment til anvendelse ifølge et af de foregående krav, hvor mennesket har en knoglerelateret lidelse, der er valgt fra gruppen bestående af akondroplasi, cleidocranial dysostose, enkondromatose, fibrøs dysplasi, Gauchers sygdom, hypofosfatæmisk rakitis, Marfans syndrom, multiple hereditære eksostoser, neurofibromatose, osteogenesis imperfecta, osteo-petrose, osteopoikilose, skierotiske læsioner, pseudoartrose, pyogen osteomyelitis, periodontal sygdom, knogletab, der er induceret af anti-epileptiske lægemidler, primær og sekundær hyperparatyroidisme, familiære hyperpara-tyroidismesyndromer, knogletab, der er induceret af vægtløshed, osteopo-rose hos mænd, postmenopausalt knogletab, osteoartritis, renal osteodystro-fi, infiltrative knoglelidelser, oralt knogletab, osteonekrose i kæben, juvenil Pagets sygdom, meloreostose, metaboliske knoglesygdomme, mastocytose, seglcelleanæmi/-sygdom, organtransplantationsrelateret knogletab, nyretransplantationsrelateret knogletab, systemisk lupus erythematosus, an-kyloserende spondylitis, epilepsi, juvenil arthritis, thalassemia, mucopolysac-charidose, Fabrys sygdom, Turners syndrom, Downs syndrom, Klinefelters syndrom, spedalskhed, Perthes sygdom, adolescent idiopatisk scoliose, IOMID - infantile onset multi-system inflammatory disease, Winchesters syndrom, Menkes sygdom, Wilsons sygdom, iskæmisk knoglesygdom, Legg-Calve-Perthes sygdom, regional migratorisk osteoporose, anæmiske tilstande, lidelser forårsaget af steroider, glukokortikoid-induceret knoglemarv, he-parin-induceret knogletab, knoglemarvslidelser, skørbug, fejlernæring, kalciummangel, osteoporose, osteopeni, alkoholisme, kronisk leversygdom, postmenopausal tilstand, kroniske inflammatoriske tilstande, reumatoid artri-tis, inflammatorisk tarmsygdom, colitis ulcerosa, inflammatorisk colitis, Crohns sygdom, oligomenoré, amenoré, graviditet, diabetes mellitus, hyper-thyroidisme, skjoldbrusklidelser, biskjoldbrusklidelser, Cushings sygdom, akromegali, hypogonadisme, immobilisering eller inaktivitet, reflektorisk sympatisk dystrofi, regional osteoporose, osteomalaci, knogletab forbundet med ledudskiftning, knogletab forbundet med HIV, knogletab forbundet med tab af væksthormon, knogletab forbundet med cystisk fibrose, knogletab forbundet med kemoterapi, tumorinduceret knogletab, cancer-relateret knogletab, hor-monablativt knogletab, myelomatose, lægemiddelinduceret knogletab, anorexia nervosa, sygdomsrelateret ansigtsknogletab, sygdomsrelateret kranieknogletab, sygdomsrelateret knogletab i kæben, sygdomsrelateret knogletab i kraniet, knogletab forbundet med aldring, ansigtsknogletab forbundet med aldring, kranieknogletab forbundet med aldring, kæbeknogletab forbundet med aldring, kranieknogletab forbundet med aldring og knogletab forbundet med rumrejser.
12. Antistof eller fragment til anvendelse ifølge et af de foregående krav, hvor mennesket er en postmenopausal kvinde.
13. Antistof eller fragment til anvendelse ifølge et af de foregående krav, hvor mennesket lider af osteoporose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97302407P | 2007-09-17 | 2007-09-17 | |
| EP08832690.5A EP2195026B1 (en) | 2007-09-17 | 2008-09-17 | Anti-sclerostin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2556841T3 true DK2556841T3 (da) | 2016-08-15 |
Family
ID=40371592
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16162068.7T DK3085386T3 (da) | 2007-09-17 | 2008-09-17 | Fremgangsmåde til hæmning af knogleresorption |
| DK20174310.1T DK3725329T3 (da) | 2007-09-17 | 2008-09-17 | Fremgangsmåde til hæmning af knogleresorption |
| DK08832690.5T DK2195026T3 (da) | 2007-09-17 | 2008-09-17 | Anti-sclerostin-antistoffer |
| DK12180292.0T DK2556841T3 (da) | 2007-09-17 | 2008-09-17 | Fremgangsmåde til hæmning af knogleresorption |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16162068.7T DK3085386T3 (da) | 2007-09-17 | 2008-09-17 | Fremgangsmåde til hæmning af knogleresorption |
| DK20174310.1T DK3725329T3 (da) | 2007-09-17 | 2008-09-17 | Fremgangsmåde til hæmning af knogleresorption |
| DK08832690.5T DK2195026T3 (da) | 2007-09-17 | 2008-09-17 | Anti-sclerostin-antistoffer |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US8017120B2 (da) |
| EP (5) | EP2195026B1 (da) |
| JP (2) | JP5643094B2 (da) |
| AR (2) | AR068471A1 (da) |
| AU (1) | AU2008302313C1 (da) |
| CA (2) | CA3170836A1 (da) |
| CL (1) | CL2008002775A1 (da) |
| CY (3) | CY1114961T1 (da) |
| DK (4) | DK3085386T3 (da) |
| ES (4) | ES2445792T3 (da) |
| FI (1) | FI3725329T3 (da) |
| HR (4) | HRP20140153T1 (da) |
| HU (3) | HUE030168T2 (da) |
| LT (3) | LT3725329T (da) |
| MX (1) | MX2010002971A (da) |
| PL (4) | PL2556841T3 (da) |
| PT (4) | PT3725329T (da) |
| SI (4) | SI2195026T1 (da) |
| TW (2) | TWI526222B (da) |
| WO (1) | WO2009039175A2 (da) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1133558E (pt) | 1998-11-27 | 2007-01-31 | Ucb Sa | Composições e métodos para aumentar a mineralização óssea |
| NZ544618A (en) * | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US20100036091A1 (en) * | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| US20100015665A1 (en) * | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
| EP2144613B1 (en) | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| US20090142766A1 (en) * | 2007-11-09 | 2009-06-04 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
| CN101896201A (zh) * | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| WO2012075422A2 (en) * | 2010-12-02 | 2012-06-07 | The Washington University | Compositions and methods for treating amyloid plaque associated symptoms |
| MX2013010011A (es) | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
| EA029956B1 (ru) | 2011-03-25 | 2018-06-29 | Эмджен Инк. | Кристаллы антител против склеростина и составы на их основе |
| PL3404041T3 (pl) * | 2011-04-19 | 2020-12-14 | Amgen Inc. | Sposób leczenia osteoporozy |
| JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
| WO2013019954A1 (en) * | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
| EP3275443A1 (en) * | 2011-09-22 | 2018-01-31 | Exelixis, Inc. | Method for treating osteoporosis |
| SG10201509629QA (en) | 2011-12-28 | 2015-12-30 | Amgen Inc | Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies |
| JP6770312B2 (ja) | 2012-07-05 | 2020-10-14 | ユセベ ファルマ ソシエテ アノニム | 骨疾患の治療 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| US10830775B2 (en) | 2014-09-30 | 2020-11-10 | Washington University | Tau kinetic measurements |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| BR112019012731A2 (pt) | 2016-12-21 | 2019-11-26 | Mereo Biopharma 3 Limited | uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTINE ANTIBODIES AND METHODS OF USE |
| US11466079B2 (en) * | 2018-03-30 | 2022-10-11 | Amgen Inc. | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| CN111658821A (zh) * | 2020-06-03 | 2020-09-15 | 深圳市百吉因生物科技有限公司 | 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用 |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| AU2024305922A1 (en) * | 2023-06-27 | 2026-01-15 | Perron Institute for Neurological and Translational Science Limited | Antisense oligomer treatment for bone loss |
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| EP0640688A1 (en) | 1987-12-15 | 1995-03-01 | Gene Shears Pty. Limited | Ribozymes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| AU662304B2 (en) | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| CA2164505A1 (en) | 1993-06-07 | 1994-12-22 | Phillip W. Berman | Hiv envelope polypeptides |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| JPH10511840A (ja) | 1994-04-29 | 1998-11-17 | クリエイティブ バイオモレキュールズ，インコーポレイテッド | 形態形成タンパク質特異細胞表面レセプターおよびその使用 |
| US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| WO1997044461A2 (en) | 1996-05-22 | 1997-11-27 | Novopharm Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| WO1999006554A2 (en) | 1997-08-01 | 1999-02-11 | Genset | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| GB9818881D0 (en) * | 1998-08-28 | 1998-10-21 | Glaxo Group Ltd | Compounds |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| PT1133558E (pt) | 1998-11-27 | 2007-01-31 | Ucb Sa | Composições e métodos para aumentar a mineralização óssea |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| AU3475100A (en) | 1999-01-29 | 2000-08-18 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| AU4851900A (en) | 1999-06-09 | 2000-12-28 | Genentech Inc. | Compositions and methods for the treatment of tumor |
| US6197592B1 (en) | 1999-07-15 | 2001-03-06 | Bio-Rad Laboratories, Inc. | Clinical control materials for detection of bone resorptive markers |
| JP4141095B2 (ja) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | 半導体装置とその製造方法 |
| AU4196801A (en) | 2000-03-02 | 2001-09-12 | Amgen Inc | Chordin-like-2 molecules and uses thereof |
| EP1290169A2 (en) | 2000-06-01 | 2003-03-12 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| JP2004520005A (ja) | 2000-06-19 | 2004-07-08 | エフ．ホフマン−ラ ロシュ アーゲー | オステオレビン遺伝子多型性 |
| CA2421056A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | A polypeptide for use as a diagnostic marker for the presence of colon tumours |
| CA2423227C (en) | 2000-10-12 | 2011-11-29 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| NZ533051A (en) | 2001-12-06 | 2006-10-27 | Biocontrol Systems Inc | Sample collection and testing system |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| JP4662714B2 (ja) | 2002-03-01 | 2011-03-30 | セルテック アール アンド ディー インコーポレイテッド | 骨密度を増減させる方法 |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| ES2379689T3 (es) | 2003-03-14 | 2012-04-30 | Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware | Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo |
| EP1608733B1 (en) | 2003-04-02 | 2011-12-07 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| NZ544618A (en) | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| DE602005017362D1 (de) | 2004-02-06 | 2009-12-10 | Dharmacon Inc | Stabilisierte rnas als transfektionskontrollen und silencing-reagentien |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
| CA2574881C (en) | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US8541177B2 (en) * | 2006-01-13 | 2013-09-24 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
| US20100015665A1 (en) | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| US20080120672A1 (en) | 2006-11-21 | 2008-05-22 | Francesco Caggioni | Methods and Apparatus for Weighted Multicasting of Data Streams |
| EP2144613B1 (en) | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| MX2009008096A (es) | 2007-02-02 | 2009-08-07 | Novartis Ag | Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos. |
| JP2010524846A (ja) | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | 抗スクレロスチン抗体 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| ES2663077T3 (es) | 2007-11-02 | 2018-04-11 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6) |
| CN101896201A (zh) | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
| EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| MX354481B (es) | 2010-10-27 | 2018-03-07 | Amgen Inc | Anticuerpos dkk1 y métodos de uso. |
-
2008
- 2008-09-16 CL CL2008002775A patent/CL2008002775A1/es unknown
- 2008-09-17 SI SI200831170T patent/SI2195026T1/sl unknown
- 2008-09-17 HU HUE12180292A patent/HUE030168T2/en unknown
- 2008-09-17 ES ES08832690.5T patent/ES2445792T3/es active Active
- 2008-09-17 HR HRP20140153AT patent/HRP20140153T1/hr unknown
- 2008-09-17 PT PT201743101T patent/PT3725329T/pt unknown
- 2008-09-17 DK DK16162068.7T patent/DK3085386T3/da active
- 2008-09-17 ES ES20174310T patent/ES2975587T3/es active Active
- 2008-09-17 MX MX2010002971A patent/MX2010002971A/es active IP Right Grant
- 2008-09-17 EP EP08832690.5A patent/EP2195026B1/en active Active
- 2008-09-17 DK DK20174310.1T patent/DK3725329T3/da active
- 2008-09-17 SI SI200831663A patent/SI2556841T1/sl unknown
- 2008-09-17 JP JP2010525108A patent/JP5643094B2/ja active Active
- 2008-09-17 EP EP16162068.7A patent/EP3085386B1/en not_active Revoked
- 2008-09-17 HR HRP20240493TT patent/HRP20240493T3/hr unknown
- 2008-09-17 SI SI200832217T patent/SI3725329T1/sl unknown
- 2008-09-17 PT PT161620687T patent/PT3085386T/pt unknown
- 2008-09-17 EP EP23219258.3A patent/EP4335510A3/en active Pending
- 2008-09-17 ES ES16162068T patent/ES2815677T3/es active Active
- 2008-09-17 AR ARP080104044A patent/AR068471A1/es not_active Application Discontinuation
- 2008-09-17 AU AU2008302313A patent/AU2008302313C1/en active Active
- 2008-09-17 CA CA3170836A patent/CA3170836A1/en active Pending
- 2008-09-17 SI SI200832137T patent/SI3085386T1/sl unknown
- 2008-09-17 LT LTEP20174310.1T patent/LT3725329T/lt unknown
- 2008-09-17 DK DK08832690.5T patent/DK2195026T3/da active
- 2008-09-17 HU HUE20174310A patent/HUE066466T2/hu unknown
- 2008-09-17 CA CA2699905A patent/CA2699905C/en active Active
- 2008-09-17 TW TW097135666A patent/TWI526222B/zh active
- 2008-09-17 FI FIEP20174310.1T patent/FI3725329T3/fi active
- 2008-09-17 PL PL12180292.0T patent/PL2556841T3/pl unknown
- 2008-09-17 PL PL20174310.1T patent/PL3725329T3/pl unknown
- 2008-09-17 PT PT88326905T patent/PT2195026E/pt unknown
- 2008-09-17 TW TW104134720A patent/TWI612972B/zh active
- 2008-09-17 WO PCT/US2008/076679 patent/WO2009039175A2/en not_active Ceased
- 2008-09-17 PL PL16162068T patent/PL3085386T3/pl unknown
- 2008-09-17 DK DK12180292.0T patent/DK2556841T3/da active
- 2008-09-17 HU HUE16162068A patent/HUE050653T2/hu unknown
- 2008-09-17 LT LTEP12180292.0T patent/LT2556841T/lt unknown
- 2008-09-17 EP EP20174310.1A patent/EP3725329B1/en active Active
- 2008-09-17 EP EP12180292.0A patent/EP2556841B9/en not_active Revoked
- 2008-09-17 PT PT121802920T patent/PT2556841T/pt unknown
- 2008-09-17 LT LTEP16162068.7T patent/LT3085386T/lt unknown
- 2008-09-17 ES ES12180292.0T patent/ES2581754T3/es active Active
- 2008-09-17 US US12/212,327 patent/US8017120B2/en active Active
- 2008-09-17 PL PL08832690T patent/PL2195026T3/pl unknown
-
2011
- 2011-04-19 US US13/090,058 patent/US8329176B2/en active Active
- 2011-04-19 US US13/090,075 patent/US8440193B2/en active Active
-
2013
- 2013-04-11 US US13/860,954 patent/US9089553B2/en active Active
-
2014
- 2014-03-07 CY CY20141100183T patent/CY1114961T1/el unknown
- 2014-09-03 JP JP2014178609A patent/JP5764704B2/ja active Active
-
2015
- 2015-06-16 US US14/740,838 patent/US10273293B2/en active Active
-
2016
- 2016-07-14 HR HRP20160872TT patent/HRP20160872T1/hr unknown
- 2016-07-15 CY CY20161100685T patent/CY1117908T1/el unknown
-
2017
- 2017-10-27 AR ARP170103001A patent/AR109995A2/es unknown
-
2018
- 2018-11-14 US US16/191,068 patent/US11091537B2/en active Active
-
2020
- 2020-09-02 CY CY20201100823T patent/CY1123463T1/el unknown
- 2020-09-09 HR HRP20201438TT patent/HRP20201438T1/hr unknown
-
2021
- 2021-07-15 US US17/376,304 patent/US12421304B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2556841T3 (da) | Fremgangsmåde til hæmning af knogleresorption | |
| KR101653122B1 (ko) | 스클레로스틴 결합제 | |
| DK2301961T3 (da) | Sclerostin-epitoper | |
| KR20100101656A (ko) | 항-스클레로스틴 항체를 사용한 골절 치료 방법 | |
| KR102033669B1 (ko) | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 | |
| AU2013285488B2 (en) | Treatment for bone diseases | |
| HK1150783A (en) | Method for treating bone fracture with anti-sclerostin antibodies | |
| HK1192260B (zh) | Sclerostin结合剂 |